What is he best known for?
The fields of study he is best known for:
His scientific interests lie mostly in Immune system, Immunology, Virology, Antigen and DNA vaccination.
Jean D. Boyer studies Humoral immunity which is a part of Immune system.
In general Immunology study, his work on Acquired immune system, Immunotherapy and CTL* often relates to the realm of CD80 and Standardization, thereby connecting several areas of interest.
His Virology study integrates concerns from other disciplines, such as Cellular immunity, Viral vector, Immunization and DNA.
Jean D. Boyer has researched Antigen in several fields, including T cell and Antibody.
His DNA vaccination research is multidisciplinary, relying on both Adjuvant, Immunity, Immunogenicity and Vaccination.
His most cited work include:
- Gene inoculation generates immune responses against human immunodeficiency virus type 1. (681 citations)
- First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response (550 citations)
- Gene transfer in humans using a conditionally replicating lentiviral vector (454 citations)
What are the main themes of his work throughout his whole career to date?
Jean D. Boyer mainly focuses on Immunology, Immune system, Virology, DNA vaccination and Vaccination.
The Immune system study combines topics in areas such as Viral replication and Antigen.
His Antigen research is multidisciplinary, incorporating elements of Dysplasia and Recombinant DNA.
His work deals with themes such as Immunization and Immunity, which intersect with Virology.
His study in DNA vaccination is interdisciplinary in nature, drawing from both Interleukin 12, Adjuvant, HIV vaccine and AIDS Vaccines.
He has included themes like HIV Antigens, Seroconversion, DNA and Immunogen in his Vaccination study.
He most often published in these fields:
- Immunology (64.84%)
- Immune system (54.40%)
- Virology (51.10%)
What were the highlights of his more recent work (between 2014-2021)?
- Immunogenicity (25.82%)
- Internal medicine (15.38%)
- Immune system (54.40%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Immunogenicity, Internal medicine, Immune system, Immunotherapy and Oncology.
Jean D. Boyer works mostly in the field of Immunogenicity, limiting it down to topics relating to DNA vaccination and, in certain cases, Vaccination, Virology, HIV vaccine, Ebola virus and Clinical trial.
His Internal medicine research includes elements of ELISPOT and Seroconversion.
His Immune system study deals with the bigger picture of Immunology.
His Immunotherapy study combines topics from a wide range of disciplines, such as Cancer research and Antigen.
His Oncology study also includes
- Prostate cancer, which have a strong connection to Myeloid,
- Radiation therapy, which have a strong connection to Cervical cancer and Adjuvant.
Between 2014 and 2021, his most popular works were:
- Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. (339 citations)
- Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. (149 citations)
- Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. (120 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Virus
- Cancer
Internal medicine, Immunogenicity, Tolerability, Adverse effect and Immunotherapy are his primary areas of study.
Jean D. Boyer regularly ties together related areas like DNA vaccination in his Immunogenicity studies.
Jean D. Boyer combines subjects such as Regimen, Ebola virus, Virology and Zika virus with his study of DNA vaccination.
While the research belongs to areas of Adverse effect, Jean D. Boyer spends his time largely on the problem of Vaccination, intersecting his research to questions surrounding Clinical trial.
His study with FOXP3 involves better knowledge in Immune system.
His Cancer study frequently links to related topics such as Immunology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
